Kidswell Bio Corporation (TYO:4584)

Market Cap	11.01B
Revenue (ttm)	5.08B
Net Income (ttm)	-21.00M
Shares Out	43.88M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	24.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,959,700
Average Volume	7,550,215
Open	276.00
Previous Close	279.00
Day's Range	251.00 - 276.00
52-Week Range	88.00 - 417.00
Beta	0.96
RSI	46.23
Earnings Date	Aug 12, 2025

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 38
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4584

Financial Performance

In 2024, Kidswell Bio's revenue was 5.08 billion, an increase of 223.90% compared to the previous year's 1.57 billion. Losses were -21.00 million, -96.07% less than in 2021.